1. AutoMax receives first shipment from JAC Motors, enhancing distribution capabilities. 2. SciSparc's merger with AutoMax aims to expand into the automotive sector. 3. Regulatory approvals now allow AutoMax to market JAC Motors vehicles in Israel. 4. Financial support from SciSparc facilitated AutoMax’s operations and growth. 5. The merger is subject to shareholder approval, impacting future plans.

1. iLearningEngines filed for Chapter 11 bankruptcy on December 20, 2024. 2. The company plans to continue operations and serve its customers during the process. 3. Interim CEO Tom Olivier emphasizes stakeholder support for a stronger future. 4. Legal advisors have been appointed for guidance throughout the bankruptcy proceedings. 5. The outcome remains uncertain due to risks related to the bankruptcy process.

1. Prosus agrees to acquire Despegar at $19.50 per share, a 33% premium. 2. Despegar's board supports the acquisition, stating strong value for shareholders. 3. This expands Prosus's Latin America ecosystem to over 100 million customers. 4. Despegar projects significant growth leveraging Prosus’s resources and expertise. 5. Online travel is strengthening in Latin America, promising future engagement.

1. Despegar will be acquired by Prosus for $19.50 per share. 2. Transaction represents a 34% premium over recent trading prices. 3. Despegar gains Prosus's resources, enhancing growth and innovation capabilities. 4. The deal expected to close in Q2 2025, pending approvals. 5. Despegar will be delisted from NYSE post-transaction completion.

1. Anavex reports MAA acceptance for blarcamesine by EMA for Alzheimer's treatment. 2. Company has $132.2 million cash, sufficient for about 4 years at current rate. 3. Upcoming data presentation at J.P. Morgan Healthcare Conference in January 2025. 4. Net loss for Q4 2024 was $11.6 million, slightly worse than last year. 5. Alzheimer's disease affects 7 million in Europe, expected to double by 2030.

1. Net sales decreased 9% but net income increased 29% in Q3 2024. 2. Backlog reached $114.2 million, reflecting strong business growth. 3. Fiscal 2024 year-to-date net income is highest since 2017 transition. 4. Increased infrastructure spending in Middle Eastern regions supports growth. 5. General and administrative expenses rose due to payroll and fees.

1. LYTENAVA™ is the first approved drug for wet AMD in the EU and UK. 2. First commercial launch in the UK and Germany expected in H1 CY25. 3. Received NICE recommendation as a treatment option for wet AMD. 4. Annual net loss for FY2024 was $75.4 million, higher than FY2023. 5. Final efficacy and safety data from NORSE EIGHT due in January 2025.

1. FlexShopper expects Q4 2024 results to exceed Q4 2023. 2. Lease gross revenue grew 15% and net revenue increased over 25%. 3. New loan originations surged over 34% year-over-year. 4. Company has expanded access to over 5,600 retail locations. 5. DTC and B2B strategies are driving strong holiday season performance.

1. Honda, Nissan, and Mitsubishi discuss a potential three-way merger. 2. The merger aims to compete with Chinese brands' electric vehicle market share. 3. Market conditions challenge Japanese automakers, sidelining them against Toyota's resilience. 4. Carlos Ghosn doubts the merger's success due to industrial duplications. 5. Executives emphasize significant synergies through business integration by January.

1. Honda and Nissan are considering a merger to create a joint holding company. 2. Projected combined sales of $191 billion, aiming for an operating profit of $19 billion. 3. This merger would make Honda-Nissan the third-largest automaker globally by sales. 4. Both automakers face intense competition from Tesla and BYD in the EV market. 5. Negotiations are expected to conclude by mid-2025, with a holding company by 2026.